1. Home
  2. DIN vs EDIT Comparison

DIN vs EDIT Comparison

Compare DIN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DIN

Dine Brands Global Inc.

HOLD

Current Price

$35.00

Market Cap

399.8M

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.23

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DIN
EDIT
Founded
1958
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
399.8M
432.8M
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
DIN
EDIT
Price
$35.00
$3.23
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$29.00
$5.30
AVG Volume (30 Days)
239.2K
2.1M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
2.78%
N/A
EPS Growth
N/A
37.50
EPS
0.92
N/A
Revenue
$879,300,000.00
$31,937,000.00
Revenue This Year
$3.61
N/A
Revenue Next Year
$0.64
N/A
P/E Ratio
$39.26
N/A
Revenue Growth
8.25
132.64
52 Week Low
$22.38
$1.66
52 Week High
$39.68
$4.54

Technical Indicators

Market Signals
Indicator
DIN
EDIT
Relative Strength Index (RSI) 55.38 56.64
Support Level $33.50 $2.74
Resistance Level $36.99 $3.21
Average True Range (ATR) 1.35 0.20
MACD 0.01 0.04
Stochastic Oscillator 74.78 69.23

Price Performance

Historical Comparison
DIN
EDIT

About DIN Dine Brands Global Inc.

Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: